Pfizer Overview
Pfizer is a research-based pharmaceutical company. Pfizer discovers, develops, manufactures and markets leading prescription medicines and many of the world's best-known consumer brands. Pfizer also collaborates with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world. Pfizer Pharmaceuticals Israel Ltd operates as a subsidiary of Pfizer. The company has sales office in Israel, and it also collaborates and partners with startups like CytoReason in 2019, and research institutes like the Technion Rappaport Institute in 2016.
Latest News
growth-positive
Amazon upgraded, Adobe downgraded: Wall Street’s top analyst calls
The article compiles recent research calls from Wall Street, highlighting upgrades and downgrades of various companies. Amazon.com received an upgrade from Wells Fargo, which increased its price target due to anticipated revenue acceleration in Amazon Web Services. ServiceNow was upgraded by Morgan Stanley, citing its potential in delivering generative AI capabilities. General Motors, Quanta Services, and OpenText also received upgrades. Conversely, Adobe, Keurig Dr Pepper, Bloom Energy, Knight-Swift, and Arvinas were downgraded by different firms due to various concerns, including revenue deceleration and market uncertainties.
growth-positive
Amazon upgraded, Adobe downgraded: Wall Street's top analyst calls
The article highlights recent research calls on Wall Street, focusing on upgrades and downgrades of various companies. Amazon.com was upgraded by Wells Fargo to Overweight with a higher price target, citing increased confidence in Amazon Web Services revenue acceleration. ServiceNow was also upgraded by Morgan Stanley due to its potential in delivering generative AI capabilities. Other companies like General Motors, Quanta Services, and OpenText received upgrades based on various strategic and financial factors. Conversely, companies like Adobe, Keurig Dr Pepper, Bloom Energy, Knight-Swift, and Arvinas faced downgrades due to concerns over growth, market conditions, and strategic uncertainties.
growth-positive
Padcev-Keytruda combo approved for NHS use in mUC
The National Institute for Health and Care Excellence (NICE) has recommended the combination of Astellas Pharma and Pfizer’s Padcev with MSD’s Keytruda for treating metastatic urothelial carcinoma (mUC) on the NHS. This approval follows successful commercial deals that made the treatment cost-effective. The combination, already approved by the FDA, EC, and MHRA, is now the standard of care for first-line mUC treatment, showing a 55% reduction in disease progression or death. Analysts predict that Padcev-Keytruda will capture significant market share from Bristol Myers Squibb’s Opdivo. While Keytrudas sales are expected to peak in 2027, they may decline post-2028 due to patent expirations. Meanwhile, Padcevs sales are projected to grow, with ongoing trials exploring its efficacy in other cancers.
Product StagePartners
growth-positive
Latest Fed cut signals, pharma relief rally, Apple TV+ price hike
Apple has announced a 30% price increase for its Apple TV+ subscription service, raising the monthly cost to $12.99. This price hike is effective immediately and is part of a broader trend of adjustments in the market. The increase is seen as a growth-positive move for Apple, potentially boosting its revenue from the streaming service. Meanwhile, pharmaceutical stocks, including Teva, Pfizer, and Eli Lilly, experienced a positive impact following the announcement of a US-EU trade deal that imposed a 15% tariff on pharmaceutical goods, alleviating fears of much higher tariffs. Additionally, Walmart shares fell after a profit miss, despite raising its sales guidance for the year.
growth-positive
Saudi Arabia Osteoporosis Drugs Market Analysis Report 2025-2033 Featuring Amgen, Eli Lilly and Co, F. Hoffmann La Roche, GlaxoSmithKline, Merck, Novartis, Pfizer, Teva Pharmaceutical, UCB
The Saudi Arabian Osteoporosis Drugs Market is projected to grow significantly, driven by an aging population, increasing osteoporosis rates, and favorable healthcare regulations. The market is expected to expand from $210.89 million in 2024 to $308.84 million by 2033, with a CAGR of 4.33% from 2025. While bisphosphonates remain popular due to cost-effectiveness, biologics are anticipated to grow rapidly. Government initiatives under Vision 2030 are enhancing local drug production and healthcare infrastructure, improving drug accessibility. However, challenges such as low adherence and rural access persist. Key players include Amgen, Eli Lilly, and Pfizer. The market is concentrated in urban areas, with rural regions facing limited access to experts and treatments.
Team Members
5
Employees: 51-200
Web & Social Links
| Website | www.pfizer.com/ |
Locations
Arieh Shenkar Street 7, Herzliya, Israel
New York, NY, USA
Photos & Videos
No files yet
Pfizer Business
Business models
—
Product stage
—
Employees
51-200
Sector
—Target Customer
—Core Technology
—Tags (5)
vaccinespharmaceuticalsgeneric-drugsdrug-developmentinnovation-centerPfizer Financials
—
Total funding
—
Capital raised
—
Last funding
—
Funding stage
—
Total rounds
—
Investors
Pfizer Lifecycle
Pfizer News
17 articles
growth-positive
Amazon upgraded, Adobe downgraded: Wall Street’s top analyst calls
The article compiles recent research calls from Wall Street, highlighting upgrades and downgrades of various companies. Amazon.com received an upgrade from Wells Fargo, which increased its price target due to anticipated revenue acceleration in Amazon Web Services. ServiceNow was upgraded by Morgan Stanley, citing its potential in delivering generative AI capabilities. General Motors, Quanta Services, and OpenText also received upgrades. Conversely, Adobe, Keurig Dr Pepper, Bloom Energy, Knight-Swift, and Arvinas were downgraded by different firms due to various concerns, including revenue deceleration and market uncertainties.
growth-positive
Amazon upgraded, Adobe downgraded: Wall Street's top analyst calls
The article highlights recent research calls on Wall Street, focusing on upgrades and downgrades of various companies. Amazon.com was upgraded by Wells Fargo to Overweight with a higher price target, citing increased confidence in Amazon Web Services revenue acceleration. ServiceNow was also upgraded by Morgan Stanley due to its potential in delivering generative AI capabilities. Other companies like General Motors, Quanta Services, and OpenText received upgrades based on various strategic and financial factors. Conversely, companies like Adobe, Keurig Dr Pepper, Bloom Energy, Knight-Swift, and Arvinas faced downgrades due to concerns over growth, market conditions, and strategic uncertainties.
growth-positive
Padcev-Keytruda combo approved for NHS use in mUC
The National Institute for Health and Care Excellence (NICE) has recommended the combination of Astellas Pharma and Pfizer’s Padcev with MSD’s Keytruda for treating metastatic urothelial carcinoma (mUC) on the NHS. This approval follows successful commercial deals that made the treatment cost-effective. The combination, already approved by the FDA, EC, and MHRA, is now the standard of care for first-line mUC treatment, showing a 55% reduction in disease progression or death. Analysts predict that Padcev-Keytruda will capture significant market share from Bristol Myers Squibb’s Opdivo. While Keytrudas sales are expected to peak in 2027, they may decline post-2028 due to patent expirations. Meanwhile, Padcevs sales are projected to grow, with ongoing trials exploring its efficacy in other cancers.
Product StagePartners
growth-positive
Latest Fed cut signals, pharma relief rally, Apple TV+ price hike
Apple has announced a 30% price increase for its Apple TV+ subscription service, raising the monthly cost to $12.99. This price hike is effective immediately and is part of a broader trend of adjustments in the market. The increase is seen as a growth-positive move for Apple, potentially boosting its revenue from the streaming service. Meanwhile, pharmaceutical stocks, including Teva, Pfizer, and Eli Lilly, experienced a positive impact following the announcement of a US-EU trade deal that imposed a 15% tariff on pharmaceutical goods, alleviating fears of much higher tariffs. Additionally, Walmart shares fell after a profit miss, despite raising its sales guidance for the year.
growth-positive
Saudi Arabia Osteoporosis Drugs Market Analysis Report 2025-2033 Featuring Amgen, Eli Lilly and Co, F. Hoffmann La Roche, GlaxoSmithKline, Merck, Novartis, Pfizer, Teva Pharmaceutical, UCB
The Saudi Arabian Osteoporosis Drugs Market is projected to grow significantly, driven by an aging population, increasing osteoporosis rates, and favorable healthcare regulations. The market is expected to expand from $210.89 million in 2024 to $308.84 million by 2033, with a CAGR of 4.33% from 2025. While bisphosphonates remain popular due to cost-effectiveness, biologics are anticipated to grow rapidly. Government initiatives under Vision 2030 are enhancing local drug production and healthcare infrastructure, improving drug accessibility. However, challenges such as low adherence and rural access persist. Key players include Amgen, Eli Lilly, and Pfizer. The market is concentrated in urban areas, with rural regions facing limited access to experts and treatments.
growth-negative
Stocks to watch next week: BP, Diageo, Disney, Uber and WPP
BP is set to release its second-quarter results amid declining oil and gas prices, with analysts expecting earnings of $1.35 per share and $60 billion in revenue. The company is under pressure due to weak cash flow, rising net debt, and challenges in its transition to cleaner energy sources. Activist investor Elliott has raised concerns over BPs performance, particularly its lagging shareholder returns. Analysts predict a pre-tax profit of $4.6 billion, up from $4.2 billion in Q1, but still below past levels. BPs cash flow and net debt, forecasted to be $24.9 billion by Q1 2025, remain key issues.
growth-negative
Trump Aims Tariff Double Whammy at Industries, Nations by Aug. 1
The article discusses President Donald Trumps plans to implement industry-specific tariffs alongside country-specific duties, aiming to reshape the USs global trade standing. A 50% duty on copper is expected to be announced soon, with potential tariffs on pharmaceuticals, semiconductors, lumber, chips, critical minerals, and drugs to follow. These tariffs, under Section 232 of the Trade Expansion Act, are justified on national security grounds. The European Union, Japan, and India are attempting to negotiate lower rates. The financial markets view Trumps tariff strategy as a negotiating tactic rather than a long-term economic threat.
growth-positive
AMD extends gains, solar stocks plummet, pharma stocks
Advanced Micro Devices (AMD) experienced a positive stock performance as its shares rose following a price target increase by Piper Sandler. The company is expected to recover in its GPU business by Q4, despite facing $800 million in charges due to US chip curbs. In contrast, solar energy stocks like Enphase, First Solar, and SolarEdge saw declines after Senate Republicans proposed phasing out clean energy tax credits by 2028. Additionally, pharmaceutical companies such as Eli Lilly, Pfizer, and Abbvie are under pressure due to potential changes in direct-to-consumer advertising policies. The market is also affected by geopolitical tensions between Israel and Iran.
Growth-Negative
Unlike Pfizer, Moderna can meet 2023 COVID forecast, analysts say
The article discusses various issues impacting multiple companies. Meta faces a ban on targeted advertising in the EU, which could result in fines. Bayer has been ordered to pay $332 million in damages in a glyphosate lawsuit. Royal Bank of Canada has injected $2.95 billion into its US unit, City National Bank. TE Connectivity has reported a profit due to steady demand from EV makers. DuPont has cut its revenue forecast due to sluggish demand and plans additional restructuring. Norwegian Cruise has trimmed its profit forecast due to higher costs and geopolitical events. Nvidias shares have dropped following a report of canceled China orders worth up to $5 billion due to new US government restrictions.
CustomersInvestmentManagement ChangesLayoffs
Neutral
Column: How CEOs are threading the needle in talking about Israel and Gaza
The article discusses the response of American corporate leaders to the Oct. 7 Hamas terror attack on Israeli civilians. Many companies, including Pfizer, Citigroup, American Express, Walmart, Verizon, Walt Disney Co., IBM, and Starbucks, have issued statements condemning the attack and antisemitism, pledging financial support for humanitarian relief organizations, and expressing support for their employees and their families in Israel. The article also mentions the increasing expectation among consumers and workers for corporate leaders to address social and political issues.
CustomersPartners
growth-negative
Moderna Shaves Off $7 Billion in Value After Pfizer Warning
Moderna Inc., known for its Covid-19 vaccine, is facing a decline in its stock as demand for shots and treatments for the virus wanes. The company has lost $6.8 billion in market value this week after Pfizer Inc., a rival vaccine maker, cut its profit outlook due to dwindling demand for its Covid shots and pills. Modernas stock closed at its lowest since November 2020. The company is now striving to prove its messenger-RNA technology will work against other diseases, including cancer, and has a flu and Covid combo shot as well as an RSV vaccine in the works.
CustomersInvestment
Pfizer jumps as investors look past Covid vaccine forecast to possible price hikes
Growth-Negative
Pfizer’s $43 Billion Seagen Takeover Faces EU Investigation
Pfizer Inc.’s proposed $43 billion takeover of Seagen Inc. is set to face an investigation from the European Union’s merger enforcers. The EU has been closely scrutinizing large biotechnology deals. Seagen disclosed that both firms will notify the deal to the European Commission, and the EU executive has accepted jurisdiction for investigating the proposed merger. EU approval is a condition for the deal to close. In the US, the Federal Trade Commission will also subject the proposed merger to an in-depth antitrust review.
Acquisition
growth-positive
A "boost for Jerusalem": German biotech company to open vaccine manufacturing plant in capital | CTech
Jerusalem Mayor Moshe Lion announced at a conference that an agreement has been signed between the Israeli government, BioNTech, Hadassah Hospital, and the Hebrew University to establish a development, research, and production center for mRNA-based vaccines in Jerusalem. This partnership is seen as a huge vote of confidence in Jerusalems economy and will provide a significant boost to the citys economy. Mayor Lion also invited attendees to visit Jerusalem and contribute to the opportunity.
PartnersInvestment
N/A
CytoReason, Pfizer ink $110M, 5-year extension of AI-powered drug development deal
The article does not provide any information about Questex LLC or any specific event.
growth-positive
Pfizer Taps Israeli Machine Learning Drug Discovery Company CytoReason
Pfizer has signed a collaboration agreement with CytoReason, a biotech company based in Tel Aviv. Under the agreement, CytoReason will receive payments potentially equaling up to low double digit millions of dollars for technology access fees, research support, and milestone payments. This collaboration is CytoReasons fifth partnership with a major drug company. CytoReason develops a machine learning model of the human immune system for drug discovery purposes.
Partners
growth-positive
BioRap Technologies to collaborate with Pfizer on developing new immunomodulators
BioRap Technologies, the technology transfer company of the Rappaport Institute for Biomedical Research at the Technion, has entered into an agreement with Pfizer to further develop a monoclonal antibody for potential new treatment options for chronic autoimmune diseases. Pfizer has an exclusive option to obtain a license to the monoclonal antibody program, and BioRap Technologies will receive financial support and royalties from Pfizer. The collaboration aims to create therapeutic value for patients with chronic autoimmune diseases.
Partners
Pfizer Team
Employee Info
| Employees (range) | 51-200 |
| Exact count | 174 |
| Team members | 5 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
Pfizer Internal
Recent Updates
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-02-27 19:27:25.000000
Eran Levin
· eranl@sncentral.org · Automatic · 2024-12-05 15:07:48.000000
Eran Levin
· eranl@sncentral.org · Automatic · 2024-12-05 14:12:06.000000
Eran Levin
· eranl@sncentral.org · Automatic · 2024-08-07 05:00:59.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2024-07-17 13:59:23.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2024-07-17 13:59:23.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-03-13 09:42:47.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-03-13 09:42:19.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-02-27 19:25:46.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-02-27 19:25:46.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-02-27 19:25:46.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-03-21 15:31:52.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-02-27 19:25:46.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2024-07-17 14:01:13.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-03-21 15:32:53.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-03-13 09:40:20.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-03-13 09:51:50.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-02-27 19:26:24.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-03-13 09:44:44.000000
Eran Levin
· eranl@sncentral.org · Automatic · 2024-08-07 05:54:31.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-03-13 09:48:40.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2024-07-17 13:59:24.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-03-13 09:47:34.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-02-27 19:26:24.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-03-13 09:45:18.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-02-27 19:25:46.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-02-27 19:25:46.000000
Eran Levin
· eranl@sncentral.org · Automatic · 2024-08-07 05:00:59.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-02-27 19:25:46.000000
Yanina Wainscheinker
· yanina.wain@gmail.com · Manual · 2019-04-26 18:36:24.000000
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 68/100 |
| Missing | product stage, sector, founding month, business model, video or image, funding rounds, markets, not claimed |
| BI Verification | Yamila Silbert |
| Crunchbase | pfizer |
| Phone | +97299700500 |
| Creator | Yanina Wainscheinker |
| Creator email | yanina.wain@gmail.com |
| Last updater | Maor Perlov |
| Updater email | maor.perlov@sncentral.org |
| Last update | 2023-03-13T00:00:00.000Z |
| Created | 2019-04-26T00:00:00.000Z |
| Status detail | Public on NYSE on Jan, 2004; |